RS-5
/ Resolute Science
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 24, 2025
Resolute Science Receives FDA Orphan Drug Designation for its Lead Therapeutic, RS-5, for Soft Tissue Sarcomas
(PRWeb)
- "This regulatory milestone underscores RS-5's therapeutic potential and supports the company's continued progress toward initiating first-in-human clinical trials in 2026."
New trial • Orphan drug • Soft Tissue Sarcoma
1 to 1
Of
1
Go to page
1